Seelos Therapeutics Past Earnings Performance
Past criteria checks 2/6
Seelos Therapeutics's earnings have been declining at an average annual rate of -6.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 64.4% per year.
Key information
-6.6%
Earnings growth rate
22.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 64.4% |
| Return on equity | n/a |
| Net Margin | 203.1% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Seelos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | 4 | 11 | 0 |
| 31 Mar 24 | 2 | -27 | 12 | 0 |
| 31 Dec 23 | 2 | -38 | 13 | 0 |
| 30 Sep 23 | 2 | -51 | 13 | -33 |
| 30 Jun 23 | 1 | -81 | 12 | 1 |
| 31 Mar 23 | 1 | -73 | 12 | 0 |
| 31 Dec 22 | 0 | -74 | 12 | 0 |
| 30 Sep 22 | 0 | -82 | 17 | 63 |
| 30 Jun 22 | 0 | -73 | 17 | 28 |
| 31 Mar 22 | 0 | -61 | 17 | 33 |
| 31 Dec 21 | 0 | -66 | 15 | 47 |
| 30 Sep 21 | 0 | -45 | 9 | 38 |
| 30 Jun 21 | 0 | -39 | 9 | 29 |
| 31 Mar 21 | 0 | -33 | 8 | 25 |
| 31 Dec 20 | 0 | -19 | 8 | 11 |
| 30 Sep 20 | 0 | -23 | 7 | 0 |
| 30 Jun 20 | 0 | -22 | 6 | -9 |
| 31 Mar 20 | 0 | -21 | 6 | -7 |
| 31 Dec 19 | 0 | -51 | 6 | 0 |
| 30 Sep 19 | 0 | -42 | 5 | 0 |
| 30 Jun 19 | 0 | -40 | 5 | 9 |
| 31 Mar 19 | 0 | -38 | 4 | 7 |
| 31 Dec 18 | 0 | -3 | 3 | 1 |
| 30 Sep 18 | 0 | -3 | 2 | 1 |
| 30 Jun 18 | 0 | -2 | 1 | 1 |
| 31 Mar 18 | 0 | -2 | 1 | 1 |
| 31 Dec 17 | 0 | -12 | 7 | 3 |
Quality Earnings: SEEL.Q has a large one-off loss of $5.4M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: SEEL.Q became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SEEL.Q has become profitable over the past 5 years, growing earnings by -6.6% per year.
Accelerating Growth: SEEL.Q has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SEEL.Q has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: SEEL.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.